Publications

Real-World Data On Patients’ Characteristics Guiding Physicians’ Choice Of First-line Treatment For Advanced Urothelial Carcinoma: Is There Still A Place For Platinum-based Chemotherapy?

Real-world Sequencing of Anti-bcma Car T-cells and Bispecific T-cell Engagers in Relapsed/refractory Multiple Myeloma: a Multi-country Analysis

Iron deficiency treatment pathway in Italy: patients’ perceptions of diagnosis and treatment.

Biologic treatment patterns and phenotyping in severe uncontrolled asthma: a multinational study.

Definitive staging and perioperative treatment for resectable Stage IB-IIIA Non-Small Cell Lung Cancer (NSCLC) a UK perspective.

Understanding ALK+ NSCLC caregivers’ psychosociological burden: Findings from the study ‘‘Living with ALK+ cancer in France’’

Real-world data on the management of potentially resectable stage IB-IIIA non-small cell lung cancer (NSCLC) in the United Kingdom (UK) in 2023: Early adoption of immune checkpoint inhibitors (ICIs).

Experiences of patients with advanced ALK+ non-small-cell lung cancer (NSCLC) in France: results of the qualitative phase of the “Living with ALK+ cancer” survey. Qualitative study conducted by APLUSA.

Key drivers for treatment choice in lenalidomide-exposed and refractory multiple myeloma patients in the real world. Analysis conducted in the EU5 countries and the US.

Estimating the impact on survival of not receiving CAR-T therapy despite being eligible in Relapsed/Refractory (R/R) diffuse large B-Cell lymphoma (dlbcl) patients in Germany.